Supplementary Figure.1 NF- κ B p65 / β- actin protein ID8HM-1 1 2 3 * * * β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) NF-κB p65 β-actin.

Slides:

Advertisements

Similar presentations

SKOV-3, 48h CaOV-3, 48h BG-1, 48h Concentration (µM) Viable cells (%) SW 43 SW IV-52s SW III-123 SW 43 + SW IV-52s SW 43 SW IV-52s SW III-123 SW 43 + SW.

Advertisements

P-ERK Total ERK Mel888 CHL1 WM BRAFi (nmol/L) Supplemental Figure 2: Other surface molecules unaffected ns PD-L1 ns MCSP DMSO BRAFi Supplemental.

Tfam 1  g empty vector 1  g Tfb2m 1  g Relative mRNA level * * p

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

PrimerSequence (5' to 3')Comments Hpt-FwCGCGACGTCTGTCGAGAAGTTT RT-PCR analysis Hpt-RvATCGGACGATTGCGTCGCATCGA RT-PCR analysis AOX1a-FwGATGTTTGTCTACTGCCGAGGATTT.

Supplementary Figure 1A-B A H1299 RH LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.

Supplemental Figure 1 Piceatannol SP , ER Inhibitors concentration (µM) A B.

Table S1. Primers for quantitative RT-PCR β-actinSense5'-ATCTGGCACCACACCTTC-3' Antisense5'-AGCCAGGTCCAGACGCA-3' CD36Sense5'-TGGTCAAGCCAGCTAGAAA-3' Antisense5'-CCCAGTCTCATTTAGCCAC-3'

Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)

A Acquire ovarian cancer cell lines from various repository ATCC (6), CRT (2), DSMZ (2), ECACC (7), Kyoto U (24), RIKEN (1) Cell line expansion & banking.

Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

Invest. Ophthalmol. Vis. Sci ;47(1): doi: /iovs Figure Legend:

Supplementary Figure 1. (A) Expression of DSB repair proteins

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Fig. 5. Effect of JGH43IA on the expression of neuronal survival and death related proteins. Western blot analysis of neuronal cell survival and death.

Figure 2. Proposed phenotypes of type 2 DCs

A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M

Table 1 Case # Age at primary Biopsy (year) Age at metastasis

A B C Supplementary Figure 1 Group 1 Group 2 Group 3 #1 #2 #3 #4 #5 #6

Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl

PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection PbA‐specific CD4 T‐cell responses are maximal at day 6 post‐pRBC infection Proportion.

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Supplementary information

Supplementary Figure S1 Supplementary Figure S2

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

(A-B) Expression of dominant negative p73. (C) Knockdown of p73

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Supplementary Figure 2. AKT1 AKT1 AKT2 pAKT ERK pERK A1847 A2780 CaOV3

TCF19 is required for survival of NRAS‐mutant melanoma cells

a c b d e * * －＋ Supplementary Figure 0.2 HCF (ALP / G3PDH) 0.1 SK-1

Relative protein levels

Nat. Rev. Endocrinol. doi: /nrendo

STAT3 regulates IgE class switching in a Th2-type response.

Supplementary Figure S1

Supplemental Figure 1 ** ** *** * FTH FTL

Supplementary Figure S4

(apoptotic + necrotic)

by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong

Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy

Glutamine addiction and cancer invasiveness are positively correlated in ovarian cancer cells (OVCA) Gln deprivation effect on proliferation rate of a.

Figure S3. Zhang et al. A B Myc-SIRT1 - + sir2a+/+ sir2a-/-

USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.

Supplementary Figure S1

Silencing Ifngr1 in the CMT167 line confers decreased response to IFNγ in vitro and in vivo. Silencing Ifngr1 in the CMT167 line confers decreased response.

Supplementary Figure S1

A B D C E F Supplementary Figure S4. Epping et al. IP: flag input IgG

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

Targeting eIF4E increases ZEB1 protein and mRNA levels and decreases ZEB1-targeting miR-200c and miR-141 microRNAs. Targeting eIF4E increases ZEB1 protein.

NK Cells Fighting Cancer

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Western blotting of PD-L1 mAbs.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Expression of B7-H1, B7-DC, and PD-1 on B cells.

Mice with a B cell–specific deletion of Ets1 have increased memory phenotype B cells but no increase in switching to IgG1. Mice with a B cell–specific.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PARP1 suppresses the transcription of PD-L1 in cancer cells.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

Influence of minocycline on TGF-β1 expression and TGF-β1–induced NF-кB activation in ovarian cancer cells. Influence of minocycline on TGF-β1 expression.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

Supplementary Figure.1 NF- κ B p65 / β- actin protein ** ID8HM ** * * * β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) NF-κB p65 β-actin NF-κB p65 AB 0 +GEM(24uM) +PTX(2uM) non-treat +CBDCA(20uM) +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +CBDCA(500uM) +CBDCA(100uM) +CPA(0.7uM) +CPA(7uM) +CPA(70uM) 0 +GEM(24uM) +PTX(2uM) non-treat +CBDCA(20uM) +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +CBDCA(500uM) +CBDCA(100uM) +CPA(0.7uM) +CPA(7uM) +CPA(70uM) * ** * * * *

Supplementary Figure.2 PD-L1 β-actin NF-κB p65 ID8 PD-L1 NF-κB p65 β-actin HM-1 +GEM(24uM)+PTX(2uM)non-treat+CBDCA(20uM)+GEM(120uM)+GEM(600uM)+PTX(10uM)+PTX(20uM)+CBDCA(100uM)+CBDCA(500uM) +GEM(24uM)+PTX(2uM)non-treat+CBDCA(20uM)+GEM(120uM)+GEM(600uM)+PTX(10uM)+PTX(20uM)+CBDCA(100uM)+CBDCA(500uM)

Supplementary Figure.3 NF-κB p65 β-actin +GEM+PTX+GEM+PTX ovary1847SK-OV-3 non-treat NF-κB p65 β-actin +GEM+PTX+GEM+PTX RMGIIOVCAR8 non-treat PD-L1 ovary1847 MHC class I β-actin +GEM(24uM)+PTX(2uM)non-treat+GEM(120uM)+GEM(600uM)+PTX(10uM)+PTX(20uM) β-actin +GEM(24uM)+PTX(2uM)non-treat+GEM(120uM)+GEM(600uM)+PTX(10uM)+PTX(20uM) PD-L1 SK-OV-3 MHC class I

PTXGEMCBDCAnon-treat ID8HM-1 PTXGEMCBDCAnon-treat * ** * MHC class I protein Supplementary Figure.4 C OVCAR8 RMGII GEM PTX MHC class I β-actin MHC class I / β- actin protein RMGIIOVCAR8 non-treat PTX GEM PTX GEM non-treat ** A B MHC class I / β- actin protein SK-OV-3 ovary ** ** +GEM(24uM) +PTX(2uM) non-treat +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +GEM(24uM) +PTX(2uM) non-treat +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) ** **

Supplementary Figure. 5 P=0.002 DTX and CAPE PD-L1/GAPDH mRNA beforeafter

PTX GEM CBDCA non-treat PD-L1 protein ID8HM-1 PTX GEM CBDCA non-treat ** PD-L1 / β- actin protein ID8HM Supplementary Figure.6 A B ** * * PD-L1 β-actin PD-L1 β-actin ID8 HM-1 +IFN-γ(500pg/ml)non-treat+IFN-γ(1ng/ml)+IFN-γ(4ng/ml) PD-L1 β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) PD-L1 β-actin CD +GEM(24uM) +PTX(2uM) non-treat +CBDCA(20uM) +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +CBDCA(500uM) +CBDCA(100uM) +CPA(0.7uM) +CPA(7uM) +CPA(70uM) +GEM(24uM) +PTX(2uM) non-treat +CBDCA(20uM) +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +CBDCA(500uM) +CBDCA(100uM) +CPA(0.7uM) +CPA(7uM) +CPA(70uM) * ** * * *

OVCAR8RMGII GEM PTX β-actin PD-L1 RMGIIOVCAR8 PD-L1 / β- actin protein PTXGEMnon-treatPTXGEMnon-treat ** PD-L1 OVCAR RMGII PD-L1 protein SK-OV-3 ovary 1847 RMGIIOVCAR8 PTXGEMnon-treatPTXGEMnon-treatPTXGEMnon-treatPTXGEMnon-treat ** Supplementary Figure.7 A B C PD-L1 / β- actin protein D +GEM(24uM) +PTX(2uM) non-treat +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) +GEM(24uM) +PTX(2uM) non-treat +GEM(120uM)+GEM(600uM) +PTX(10uM)+PTX(20uM) SK-OV-3 ovary1847 ** ** **

Supplementary Figure. 8 NF-κB p65 β-actin ID8shRela69ID8shcControlID8shRela70HM-1shRela69HM-1shControlHM-1shRela70 B Rela/GAPDH mRNA shControl shRela69shRela70 ID8HM-1 shControl shRela69shRela70 A C NF- κ B p65 / β- actin protein shControl shRela69shRela70 ID8HM-1 shControl shRela69shRela * * * * * ** *

MHC class I protein ID8shRela69 ID8shControl non-treat PTX GEM non-treat PTX GEM * ** Supplementary Figure.9

SK-OV-3 ovary 1847 OVCAR8 NF- κ B p65 / β- actin protein siControlsiNF-κB p65siControlsiNF-κB p65siControlsiNF-κB p65 PTX non-treat GEM A ** MHC class I GEM PTX OVCAR8 siControl OVCAR8 siNF-κB p65 β-actin NF-κB p65 PD-L1 Supplementary Figure.10 C OVCAR ** siControlsiNF-κB p65 GEM PTX non-treat MHC class I / β- actin protein GEM PTX non-treat PD-L1 / β- actin protein OVCAR ** siControlsiNF-κB p65 D B

PD-L1 NF-κB p65 β-actin +GEM+PTX+GEM+PTXsiControl siNF-κB p65 MHC class I ovary1847 Supplementary Figure.11 +GEM+PTX+GEM+PTXsiControl PD-L1 NF-κB p65 β-actin MHC class I SK-OV-3 siNF-κB p65 +GEM+PTX+GEM+PTXsiControl siNF-κB p65 PD-L1 NF-κB p65 β-actin MHC class I OVCAR8

Supplementary Figure.12 A NF- κ B p65 / β- actin protein siControlsiNF-kB p65 GEM PTX non-treat siControlsiNF-kB p65 ID8HM ** NF-κB p65 GEM PTX HM-1 siNF-κB p65 HM-1 siControl β-actin PD-L1 B siControlsiNF-κB p65 GEM PTX non-treat ** PD-L1 / β- actin protein GEM non-treat PTX GEM non-treat PTX GEM non-treat PTX PD-L1 / β- actin protein shRela69 shRela70 shControl ** GEM PTX HM-1 shRela69 HM-1 shRela70 β-actin PD-L HM-1 shControl C

PD-L1 NF-κB p65 β-actin +GEM+PTX+GEM+PTX ID8 siControl ID8 siNF-κB p65 NF-κB p65 β-actin +GEM+PTX+GEM+PTX HM-1 siControl HM-1 siNF-κB p65 PD-L1 Supplementary Figure.13 non-treat

PD-L1 β-actin +GEM+PTX+GEM+PTX ID8 shRela69 ID8 ShRela70 +GEM+PTX ID8 ShControl +GEM+PTX+GEM+PTX+GEM+PTX PD-L1 β-actin Supplementary Figure.14 non-treat HM-1 shRela69 HM-1 ShRela70 HM-1 ShControl

Supplementary Figure. 15 ID8 shControlID8 shIfngr1 IFNGR

PD-L1 NF-κB p65 β-actin Supplementary Figure. 16 IFN-γ GEM PTX ID8shIfngr1ID8shControl

Supplementary Figure.17 controlGEM NF-κB p65 PD-L1 CD4 + TILs CD8 + TILs NF- κ B p65 staining score controlGEM PD-L1staining score controlGEM CD8 + T cell numbers/200 ╳ controlGEM CD4 + T cell numbers/200 ╳ controlGEM ** * * B %CD107a + cell PTX -pretreated ID8-control ID8-pdl1KO OVA loading * ** * A

Supplementary Figure. 18 B A ID8pdl1 PD-L1/GAPDH mRNA PTXGEM ID8Mirpdl1 non-treat GEM PTX ID8MirControlID8pdl1 β-actin NF-κB p65 PD-L ID8Mirpdl1 PD-L1/GAPDH mRNA non-treatPTXGEM ID8MirControl ** PD-L1/GAPDH mRNA non-treatPTXGEM **

Supplementary figure.19 IgG IgG + GEM αPD-1 αPD-1 +GEM %survival days B A ID8-pdl1KO ID8-pdl1KO + GEM ID8-control + GEM ID8-control %survival days ID8-pdl1 ID8-pdl1 + GEM

Supplementary Figure.20 C GEMPTXID8OVA PD-L1 β-actin NF-κB p65 OVA β-actin ID8 OVA 1ID8 OVA 2ID8 lacZ A B * %lysis E/T ration ID8OVA ID8lacZ with OVA loading ID8lacZ D PD-L1/GAPDH mRNA ID8lacZID8OVA GEM PTX non-treat **

Supplementary Figure 21 A B CD4 + TILs/tumor(%) controlPTXαPD-1αPD-1+PTX * * * CD8 + TILs/tumor(%) controlPTXαPD-1αPD-1+PTX * * * C PD-1 + TILs/TILs(%) controlPTXαPD-1αPD-1+PTX ** *

Supplementary Figure.22 controlPTX Gr-1 controlGEM Gr-1 Gr-1 + cell numbers/200 ╳ controlPTX Gr-1 + cell numbers/200 ╳ controlGEM *